Recipharm acquires Sanofi’s UK CMO facility 14th June 2018
Recipharm has acquired Sanofi’s manufacturing centre and business in Holmes Chapel, UK, expanding its capabilities in the growing respiratory drug market with commercial drug product manufacturing. Recipharm also has an inhalation development facility in the US.
The Holmes Chapel manufacturing facility is located close to Manchester (UK) and serves several clients from the facility and a number of products. The site manufactures flutiform for Vectura Group. As part of the transaction, Sanofi has entered into a long-term supply agreement for the products currently manufactured at the facility.
The technologies at Holmes Chapel include metered dose inhalers and nasal sprays. The facility also houses development areas for dry powder inhalation technologies.The site covers 125,000 m2 and employs a team of more than 450 specialist employees.
Thomas Eldered, chief executive officer of Recipharm, said “Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel of respiratory products. As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilizing our growing franchise in development services. Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate and we see many opportunities. The experienced management team and staff have already successfully attracted new customers and we look forward to building on this from the well invested facility.”